Underutilization of prophylactic rectal indomethacin and pancreatic duct stent for prevention of post-ERCP Pancreatitis

Background and study aims  Incidence of Post-ERCP pancreatitis (PEP) ranges from 1 % to 10 % in unselected patients and as high as 25 % to 30 % in high-risk patients. Rectal indomethacin administered before or immediately after an ERCP and prophylactic pancreatic duct stent placement (PPS) are assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Issak, Abdulfatah, Elangovan, Abbinaya, Ferguson, Roy D., Waghray, Nisheet, Sandhu, Dalbir S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211473/
https://www.ncbi.nlm.nih.gov/pubmed/34222616
http://dx.doi.org/10.1055/a-1460-7776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211473/
https://www.ncbi.nlm.nih.gov/pubmed/34222616
http://dx.doi.org/10.1055/a-1460-7776

Ejemplares similares